BR112014004418A8 - método de tratamento de sintomas associados à gastroparesia feminina - Google Patents

método de tratamento de sintomas associados à gastroparesia feminina

Info

Publication number
BR112014004418A8
BR112014004418A8 BR112014004418A BR112014004418A BR112014004418A8 BR 112014004418 A8 BR112014004418 A8 BR 112014004418A8 BR 112014004418 A BR112014004418 A BR 112014004418A BR 112014004418 A BR112014004418 A BR 112014004418A BR 112014004418 A8 BR112014004418 A8 BR 112014004418A8
Authority
BR
Brazil
Prior art keywords
symptoms associated
treating symptoms
female gastroparesis
gastroparesis
female
Prior art date
Application number
BR112014004418A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014004418A2 (pt
Inventor
A Gonyer David
R Carlson Marilyn
J D'onofrio Matthew
Original Assignee
Evoke Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evoke Pharma Inc filed Critical Evoke Pharma Inc
Publication of BR112014004418A2 publication Critical patent/BR112014004418A2/pt
Publication of BR112014004418A8 publication Critical patent/BR112014004418A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112014004418A 2011-08-25 2012-08-23 método de tratamento de sintomas associados à gastroparesia feminina BR112014004418A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527563P 2011-08-25 2011-08-25
US201261583447P 2012-01-05 2012-01-05
PCT/US2012/052096 WO2013028882A1 (en) 2011-08-25 2012-08-23 Treatment of symptoms associated with female gastroparesis

Publications (2)

Publication Number Publication Date
BR112014004418A2 BR112014004418A2 (pt) 2017-03-28
BR112014004418A8 true BR112014004418A8 (pt) 2018-01-23

Family

ID=47746868

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004418A BR112014004418A8 (pt) 2011-08-25 2012-08-23 método de tratamento de sintomas associados à gastroparesia feminina

Country Status (14)

Country Link
US (1) US20130217775A1 (enExample)
EP (1) EP2747561B1 (enExample)
JP (3) JP2014524478A (enExample)
CN (1) CN103957707A (enExample)
BR (1) BR112014004418A8 (enExample)
CA (1) CA2846340A1 (enExample)
DK (1) DK2747561T3 (enExample)
ES (1) ES2683042T3 (enExample)
MX (1) MX356317B (enExample)
PL (1) PL2747561T3 (enExample)
PT (1) PT2747561T (enExample)
RU (1) RU2616520C2 (enExample)
TR (1) TR201811221T4 (enExample)
WO (1) WO2013028882A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
EP3554489A4 (en) * 2016-12-15 2020-06-17 Evoke Pharma, Inc. TREATMENT OF MODERATE AND SERIOUS GASTROPARESIS
WO2018191584A1 (en) * 2017-04-14 2018-10-18 The Johns Hopkins University Nutritional and therapeutic supplement compositions
PL3661518T3 (pl) * 2017-07-31 2024-11-18 Alfasigma S.P.A. Metody leczenia objawów gastroparezy przy użyciu leku welusetrag
WO2019051366A1 (en) * 2017-09-11 2019-03-14 Evoke Pharma, Inc. METHODS OF INTRANASAL DELIVERY OF METOCLOPRAMIDE
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281394A (enExample) 1961-07-25
US4624965A (en) 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US5760086A (en) 1996-03-14 1998-06-02 Ribogene, Inc. Nasal administration of agents for treatment of delayed onset emesis
HUP9902891A3 (en) * 1997-03-13 2000-11-28 Ribogene Inc Hayward Intranasal administration of a metoclopramide containing spray for treatment of delayed onset emesis
US6187332B1 (en) * 1999-06-14 2001-02-13 Wisconsin Alumni Research Foundation Acidic buffered nasal spray
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
US6770262B2 (en) * 2000-03-30 2004-08-03 Questcor Pharmaceuticals, Inc. Nasal administration of agents for the treatment of gastroparesis
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
WO2010075444A2 (en) * 2008-12-22 2010-07-01 Evoke Pharma, Inc. Nasal formulations of metoclopramide
JP2012521412A (ja) * 2009-03-23 2012-09-13 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． 鼻のアレルギー疾患において適用するためのクルクミノイドおよびその代謝物

Also Published As

Publication number Publication date
CN103957707A (zh) 2014-07-30
MX2014002125A (es) 2014-10-17
PL2747561T3 (pl) 2018-11-30
TR201811221T4 (tr) 2018-08-27
JP2018008979A (ja) 2018-01-18
DK2747561T3 (en) 2018-08-06
ES2683042T3 (es) 2018-09-24
JP6511492B2 (ja) 2019-05-15
RU2616520C2 (ru) 2017-04-17
EP2747561A4 (en) 2014-12-24
JP2019031551A (ja) 2019-02-28
RU2014111070A (ru) 2015-09-27
BR112014004418A2 (pt) 2017-03-28
JP2014524478A (ja) 2014-09-22
EP2747561B1 (en) 2018-05-09
PT2747561T (pt) 2018-09-28
EP2747561A1 (en) 2014-07-02
MX356317B (es) 2018-05-23
WO2013028882A1 (en) 2013-02-28
US20130217775A1 (en) 2013-08-22
CA2846340A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
BR112014021204A2 (pt) método implantado por computador
PT2774120T (pt) Método de obtenção de modo de intrapredição
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
BR112014005322A2 (pt) processo
GB201110095D0 (en) Method of treatment
EP2773754A4 (en) Methods of Treatment
BR112014009795A2 (pt) método
BR112014007958A2 (pt) método
BR112014015996A2 (pt) processo
BR112014001851A2 (pt) método
BR112014001237A2 (pt) método
LT3210978T (lt) Kalio acesulfamo gamybos būdas
BR112013022820A2 (pt) método de tratamento
BR112014009785A2 (pt) método para tratar ou reduzir efp
BR112014016001A2 (pt) processo
PL2688948T3 (pl) Sposób otrzymywania roztworu przyspieszacza
BR112014015988A2 (pt) processo
BR112013033184A2 (pt) processo
EP2824694A4 (en) PATTERN FORMATION METHOD
BR112014015999A8 (pt) processo
BR112014004418A8 (pt) método de tratamento de sintomas associados à gastroparesia feminina
IL227711A0 (en) Phenyl - isoxazol derivatives and preparation process thereof
EP2772765A4 (en) NANO ELECTRODE AND METHOD OF MANUFACTURING THEREOF
DK2476534T3 (da) Fremgangsmåde til formning
EP2809489A4 (en) LAMELLENKERN AND METHOD FOR THE PRODUCTION THEREOF

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: EVOKE PHARMA, INC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 37/18 , A61K 31/165

Ipc: A61K 31/166 (2006.01), A61K 31/165 (2006.01), A61P

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: EVOKE PHARMA, INC. (US)